Literature DB >> 9973565

Characterization of the interactions between human cdc25C, cdks, cyclins and cdk-cyclin complexes.

M C Morris1, G Divita.   

Abstract

We have overexpressed and purified human dual-specificity phosphatase cdc25C from a prokaryotic expression system at high levels and in a soluble, active form, and have studied and quantified its potential to interact with cdks, cyclins and preformed cdk-cyclin complexes by fluorescence spectroscopy and size-exclusion chromatography. Our data indicate that human cdc25C forms stable complexes, through hydrophobic contacts, with cdk and cyclin monomers, as well as with preformed cdk-cyclin complexes. In vitro, cdc25C interacts with cyclin monomers with high affinity, with tenfold less affinity with cdks, and with intermediate affinity with cdk-cyclin complexes. Moreover, changes observed in the intrinsic fluorescence of cdks, cyclins and cdk-cyclin complexes upon interaction with cdc25C are indicative of concomitant conformational changes within cdks and cyclins. From our results, we propose that in vitro, in the presence of monomeric cdks and cyclins, cdc25C forms stable ternary complexes, first through a high affinity interaction with a cyclin, which may then help target cdc25C towards a cdk. We discuss the biological relevance of our results and propose that a similar, two-step mechanism of interaction between cdc25C and cdk-cyclin complexes may occur in vivo. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9973565     DOI: 10.1006/jmbi.1998.2475

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  2 in total

1.  Poly(A) polymerase phosphorylation is dependent on novel interactions with cyclins.

Authors:  G L Bond; C Prives; J L Manley
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

2.  Functional cdc25C dual-specificity phosphatase is required for S-phase entry in human cells.

Authors:  Patric Turowski; Celine Franckhauser; May C Morris; Philippe Vaglio; Anne Fernandez; Ned J C Lamb
Journal:  Mol Biol Cell       Date:  2003-04-17       Impact factor: 4.138

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.